ProPhase Labs Inc (PRPH) Short-Term Debt to Capital

ProPhase Labs, Inc. (PRPH) relies on regular health product sales through pharmacies, ensuring a steady cash flow. The business is currently transforming its development model by expanding access to genetic testing and introducing its own dietary supplements. This chart of the company's price action reflects the 1.05 indicator, while the holding company actively invests in AI technologies for early oncology diagnostics and molecular analysis.

For ProPhase Labs, Inc. (PRPH), which is scaling rapid diagnostics, the short-term debt-to-equity ratio serves as a solvency indicator during the rapid expansion of services. The current value of 1.05 reflects the ratio of liabilities maturing within one year to equity, where low levels confirm financial stability and a sharp increase signals default risks, which is critical when choosing between long and short positions.